Gloucester Pharmaceuticals, Inc. to Present Positive Results From Multiple Romidepsin Clinical Trials at the American Society of Hematology Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gloucester Pharmaceuticals today announced four presentations from clinical trials of romidepsin at the upcoming 50th American Society of Hematology (ASH) Annual Meeting being held in San Francisco, CA, December 6 – 9, 2008. Romidepsin is a novel, cyclic peptide, histone deacetylase (HDAC) inhibitor under investigation for hematologic malignancies including cutaneous T-cell Lymphoma (CTCL), peripheral T-cell lymphoma (PTCL) and multiple myeloma.